News & Trends2026-11-13Carelogy編集部
Single Stem-Cell Injection for Feline Kidney Disease: Researchers Find No Evidence It Beat Placebo (November 2026)
On November 4, 2026, Frontiers in Veterinary Science published a randomized, placebo-controlled feasibility study of equine-derived mesenchymal stem cells given intravenously to 21 cats with chronic kidney disease. No significant treatment effect was found on blood pressure, SDMA, quality of life or IRIS stage, and the authors conclude there is no evidence the cells were more effective than control. What owners should take from a small, single-dose, exploratory trial.
What Was Published
On November 4, 2026, the journal Frontiers in Veterinary Science published an early-stage trial of stem-cell therapy for chronic kidney disease (CKD) in cats.
What the trial did:
- It enrolled 21 cats with CKD at a single veterinary practice, in a blinded, randomized, placebo-controlled design
- The cats were split into three groups of seven: (1) primed equine-derived stem cells, (2) unprimed equine-derived stem cells, and (3) placebo (saline)
- Treatment was a single intravenous injection of 3×10^5 cells in 1.0 mL
- Cats were examined on day 0 and around days 28, 56 and 84, with optional longer follow-up
The authors describe it as an exploratory feasibility study. It was not designed to settle whether the treatment works.
Source: Frontiers in Veterinary Science (November 4, 2026), de Bouvre et al.
Wondering if this applies to your cat?
Just read the news? Check a photo of your cat's face in CatsMe for signs of pain (it does not diagnose disease).
Results: No Significant Difference in Blood Pressure, SDMA, Quality of Life or Stage
The main findings reported in the paper:
- Blood pressure: the difference between groups was not statistically significant (p = 0.1543). One comparison between a stem-cell group and placebo at day 56 had an unadjusted p-value of 0.027, but it did not meet the adjusted threshold for multiple comparisons (0.006)
- SDMA (a kidney-function marker): no significant difference (p = 0.9197)
- Owner-rated quality of life: no significant difference (p = 0.9742)
- IRIS stage: no significant difference (p = 0.8230)
Safety: There were three serious adverse events — two in the placebo group and one in the primed stem-cell group. The paper judged all three unrelated to the cell product, and the authors describe the adverse events as acceptable in this small group.
The authors' conclusion: adverse events were acceptable after a single dose, but "there is no evidence that" the stem cells were more effective than the control. They call for larger studies with higher and repeated doses, and suggest blood pressure may be a useful outcome measure for future trials.
How to Read This Result
The fairer reading is not "it failed" but "at this size and under these conditions, the trial could not tell." The limitations the paper itself lists:
- Very few cats: 21 in total, seven per group. The authors acknowledge the study was underpowered to detect an effect
- A single, low dose: the authors suggest the cell number may have been too low for feline CKD
- Exploratory design: no prespecified primary efficacy endpoint
- Equine cells were used in cats
- Mixed disease severity (IRIS stage 2–3) and missing follow-up data at some time points
- Funding and interests: the study was funded by Boehringer Ingelheim Veterinary Medicine Belgium NV, which also took part in study design and analysis. The paper discloses that some authors were employed by the company or an affiliate, and that one is now at another company in which they hold shares and is an inventor on pending patents covering stem-cell use in CKD
On the positive side, no major safety problem was reported, so it works as a first step toward testing regenerative medicine in feline CKD. But it is not a result that supports the idea that stem cells will improve a cat's kidneys.
What Owners Can Do Now
There is no need to change your cat's treatment because of this news. For an owner of a cat with chronic kidney disease, what still matters most is catching changes early and managing them together with your vet.
1. If you come across material promoting stem-cell therapy, check what kind of trial it was, in how many cats, and with what result. This trial did not show effectiveness
2. Keep dated notes on drinking, urine volume, weight, appetite and any vomiting, and show them at each visit
3. Ask your vet to read blood values (SDMA, creatinine and so on) as a trend rather than a single number
4. Do not change diet or medication on your own; discuss it with your vet
Related: Early kidney disease and renal diets / Where the AIM drug FeliAIM stands / Feline kidney disease basics
Record daily changes with CatsMe
CatsMe is an app that checks a photo of a cat's face for signs of pain in its expression and keeps records you can show your vet. It does not diagnose.
Learn more about CatsMe →
Stay ahead of your cat’s health
Seen a worrying news story? Record how your cat is today. CatsMe keeps dated records for each cat.
腎臓病CKD幹細胞臨床試験ニュース2026
FAQ
CatsMeBe ready the moment you sense something's off
Take one photo and the AI checks your cat's expression for signs of pain. Keep per-cat records to review with your vet. CatsMe does not diagnose disease.